Hi, Rick,
Is there some reason we cannot establish a new trickle portfolio? If not on this thread, perhaps as a new one? A trickle watch list for those deemed a bit pricey at the present moment? I'm not the only one leaning this way, it seems:
Message 14511652
Also, does anyone have any idea what a peptide building block manufacturing capability might be worth to a biotech or pharma or a sizable trickle company? Should NZYM, mentioned as a trickle watch list candidate, be also considered a munch candidate? It's market cap is ~$43 million. $7 million is cash, it's just made a capacity increase, virtually no debt, cash flow positive, less than 2x book. It would make for a gulp with no chewing required, financially. But what kind of company would be a good fit?
Actually, I'd rather see the company prove itself. A munch at these prices wouldn't provide premium enough versus its long term chances, IMO. If it can improve its marketing, which may require some kind of business model revamping. Thinking about that.
Cheers, Tuck |
